Explore

Trendline Trendline
Oak Hill Bio Merges with SPAC to Go Public, Aiming to Advance Angelman Syndrome Treatment

Oak Hill Bio Merges with SPAC to Go Public, Aiming to Advance Angelman Syndrome Treatment

Oak Hill Bio Merges with SPAC to Go Public, Aiming to Advance Angelman Syndrome Treatment
Trendline Trendline
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Funding
Trendline Trendline
Secretome Therapeutics Expands Leadership Team to Advance Rare Disease Therapies

Secretome Therapeutics Expands Leadership Team to Advance Rare Disease Therapies

Secretome Therapeutics Expands Leadership Team to Advance Rare Disease Therapies
Trendline Trendline
Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development

Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development

Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Trendline Trendline
GSK Announces Strong Q2 Results and Plans for R Acceleration

GSK Announces Strong Q2 Results and Plans for R Acceleration

GSK Announces Strong Q2 Results and Plans for R Acceleration
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases
Trendline Trendline
Viking Therapeutics Advances Obesity Treatment Trials Amid Financial Losses

Viking Therapeutics Advances Obesity Treatment Trials Amid Financial Losses

Viking Therapeutics Advances Obesity Treatment Trials Amid Financial Losses
Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Trendline Trendline
Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments
Trendline Trendline
CSL Announces Positive Phase 3b Results for ANDEMBRY in Pediatric Hereditary Angioedema

CSL Announces Positive Phase 3b Results for ANDEMBRY in Pediatric Hereditary Angioedema

CSL Announces Positive Phase 3b Results for ANDEMBRY in Pediatric Hereditary Angioedema
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment